HHS should claim five patents on Serepta Therapeutics’ Exondys 51 (eteplirsen), a drug used to treat Duchenne muscular dystrophy, and use the patents as leverage to lower the drug’s price, said six advocacy groups in a letter to Health and Human Services Secretary Alex Azar.
Source: Drug Industry Daily